Abstract 387: Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint-inhibitor treatment response | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Abstract 387: Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint-inhibitor treatment response

Cancer Res (2021) 81 (13_Supplement): 387.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy

Yeonggyeong Park
Min Jeong Kim
Yoonhee Choi
Na Hyun Kim
Leeseul Kim
Seung Pyo Daniel Hong
Hyung-Gyo Cho
Emma Yu
Young Kwang Chae

Journal for ImmunoTherapy of Cancer (2022) 10 (3): e003566.